日本6月龄至11岁儿童COVID-19 mRNA疫苗对症状性Omicron感染的有效性
本研究在日本新潟市9家儿科诊所开展前瞻性检测阴性病例对照研究,纳入6月龄至11岁有上呼吸道症状的儿童,评估COVID-19 mRNA疫苗对症状性Omicron感染的有效性。结果显示,6月龄至4岁儿童末次接种后3个月内疫苗有效性(VE)为73%(95%CI 12-92%),5-11岁儿童接种≥2剂后3个月内VE为59%(95%CI 20-79%),但6个月后保护作用减弱或消失。
要点
- 6月龄至4岁儿童接种后3个月内VE为73%,3-6个月为64%,6个月后降至46%且无统计学意义。
- 5-11岁儿童接种≥2剂后3个月内VE为59%,3-6个月为57%,6个月后为-13%。
- 有COVID-19感染史的儿童中未观察到显著保护作用。
核心结论
- 6月龄至4岁和5-11岁儿童接种COVID-19 mRNA疫苗后6个月内对症状性Omicron感染有效,但6个月后保护作用减弱或消失。
研究设计与样本
- 前瞻性检测阴性病例对照研究,2023年4月至2024年4月在日本新潟市9家儿科诊所开展,纳入6月龄至11岁有上呼吸道症状的儿童。
主要发现
- 6月龄至4岁儿童:516例病例和2939例对照,末次接种后3个月内VE 73%(95%CI 12-92%),3-6个月VE 64%(95%CI 19-84%),6个月后VE 46%(95%CI -24%至76%)。
- 5-11岁儿童:723例病例和2745例对照,接种≥2剂后3个月内VE 59%(95%CI 20-79%),3-6个月VE 57%(95%CI 24-76%),6个月后VE -13%(95%CI -40%至9%)。
- 按COVID-19感染史分层,仅无感染史儿童在接种后3-6个月观察到显著保护:6月龄至4岁VE 70%(95%CI 21-88%),5-11岁VE 73%(95%CI 42-87%)。
临床怎么用
- 建议6月龄至11岁儿童接种COVID-19 mRNA疫苗,以在接种后6个月内获得对症状性Omicron感染的保护。
- 对有COVID-19感染史的儿童,疫苗保护作用可能有限,需结合个体情况评估接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 messenger RNA (mRNA) vaccination coverage among children remains low, especially among children aged 6 months to 4 years. In addition, data on vaccine effectiveness (VE) for this age group are limited. METHODS: A prospective, test-negative, case-control study was conducted between April 2023 and April 2024 at 9 pediatric clinics in Niigata, Japan. Patients aged 6 months to 11 years with upper respiratory tract symptoms were tested for SARS-CoV-2, and a multivariable logistic regression model was used to calculate VE against symptomatic COVID-19. RESULTS: Two Omicron outbreaks occurred, predominated by subvariants XBBs/EG.5 and BA.2.86/JN.1, respectively. Among children aged 6 months to 4 years, we included 516 cases and 2939 controls. VE was 73% (95% CI, 12-92%) within 3 months after the last vaccine dose, 64% (95% CI, 19-84%) at 3-6 months, and 46% (95% CI, -24% to 76%) at 6 months and later. Among children aged 5 to 11 years, we included 723 cases and 2745 controls and VE for those who received ≥2 doses was 59% (95% CI, 20-79%) within 3 months after the last vaccine dose, 57% (95% CI, 24-76%) at 3-6 months, and - 13% (95% CI, -40% to 9%) at 6 months and later. When stratified by history of COVID-19, statistically significant protection was observed only among children without a history of COVID-19 (at 3-6 months: 6 months to 4 years, VE 70% [95% CI, 21-88%]; 5-11 years, VE 73% [95% CI, 42-87%]). CONCLUSIONS: In children aged 6 months to 4 years, as well as those aged 5-11 years, the COVID-19 mRNA vaccine was effective against symptomatic Omicron infection within 6 months after the last dose.
引用
- Aizawa Y, Shobugawa Y, Tachikawa J, et al. Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan. Vaccine. 2026. PMID: 41844090. doi:10.1016/j.vaccine.2026.128474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。